ADAR1 Capital Management Acquires Denali Therapeutics Shares Worth $36.2 Million
Wednesday / 05/20/2026, 08:20 EST
ADAR1 Capital Management purchased 1.82 million Denali Therapeutics shares worth $36.2 million in Q1 2026, boosting its portfolio. The biotech firm focuses on neurodegenerative disease treatments.
